Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on Merck & Co. (NYSE: MRK) to $141 from $138 while maintaining a Buy rating, ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Analysts are lukewarm on Merck, giving it a “Hold” consensus with a $108.69 price target despite some bullish and bearish ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's ...

The global GMP testing service market size was US$ 1.3 billion in 2021. The global GMP testing service market size is forecast to reach US$ 2.3 billion by 2030, growing at a compound annual growth ...

Halozyme's ENHANZE technology drives strong near-term growth, but its key patent expires in 2027. Click here to find out why ...

However, Waters has announced plans to merge with BD's life science and diagnostics segment in early 2026, which will dilute that interest in that highly regulated end market, going forward. The ...

Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.

China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...